influenced by the EU MDR, notably Article 117, which mandates that products incorporating medicinal components meet specific criteria for safety and performance.

The first step in this process involves identifying the correct classification for the product. According to the EU MDR, drug-device combinations are categorized into two main groups: those where the principal intended action is that of the device (with the drug playing a complementary role), and vice versa. Understanding this classification is vital as it determines the regulatory expectations and scrutiny during the PMS/PMCF planning.

Additionally, graps of the General Safety and Performance Requirements (GSPR) is essential, as compliance with these requirements sets the foundation for the development of your PMS and PMCF plans. The GSPR is outlined in Annex I of the EU MDR and specifies a comprehensive set of safety and performance standards that a combination product must fulfill. There is also the necessity to consider relevant harmonized standards and guidelines set forth by Notified Bodies to ensure compliance.

Step 2: Develop a Comprehensive PMS Plan

Once the regulatory framework has been understood, the next step is to create a robust Post-Market Surveillance (PMS) plan. The PMS plan serves as a strategic document detailing how a company will monitor the safety and effectiveness of its combination product after it has been marketed. Here are the critical elements to include in your PMS plan:

• Objective Definition: Specify the objectives of your PMS activities, including identifying potential risks and verifying the safety and effectiveness of your product in real-world settings.
• Data Collection Methods: Establish methodologies for collecting post-market data. These methods can include passive surveillance (e.g., adverse event reporting) and active surveillance (e.g., registry studies).
• Data Analysis Plan: Define how the collected data will be analyzed, including identifying key performance indicators and safety thresholds.
• Communication Strategy: Outline the process for communicating PMS findings to healthcare professionals, regulatory authorities, and stakeholders, ensuring alignment with regulatory reporting obligations.
• Timeline and Responsibilities: Designate timelines for data collection and analysis while assigning responsibilities to specific team members or departments to ensure accountability.

The PMS plan must be tailored to the nuances of your drug-device product, adhering to EU MDR requirements while also considering FDA recommendations for combination products. It is advisable to establish a PMS working group comprising regulatory, clinical, and quality assurance experts to facilitate effective planning and execution.

Step 3: Prepare for PMCF Activities

Having developed a PMS plan, the next critical phase involves planning the Post-Market Clinical Follow-up (PMCF) activities. PMCF is a crucial element to ensure ongoing clinical safety and efficacy monitoring and often entails further clinical investigations or studies. The following steps will guide you through this process:

• Identify PMCF Objectives: Outline the clinical aspects that need further investigation. This could include evaluating long-term safety, addressing specific adverse event trends observed through PMS data, or gathering clinical data that supports the continued safety and performance of the product.
• Select Appropriate Study Design: Depending on your objectives, choose a suitable study design. This could range from observational studies to controlled trials. Ensure alignment with scientific integrity while balancing regulatory expectations.
• Engage with Notified Bodies: Prior to launching PMCF activities, consult with your Notified Body to validate your PMCF plan. This engagement can ensure alignment with regulatory expectations and streamline approval processes.
• Document and Submit PMCF Plans: Once your PMCF plan is finalized, comprehensively document all methodologies, objectives, and expected outcomes. This documentation becomes part of the technical dossier required for Notified Body review under the EU MDR guidelines.
• Data Management: Develop a robust data management plan to handle clinical data. Ensure compliance with personal data protection regulations (e.g., GDPR) throughout the PMCF activities.

PMCF must be a proactive endeavor, and continuous evaluation based on feedback from both PMS data and active clinical monitoring is vital. Regular updates to your PMCF program are essential as new data emerges or the market landscape changes.

Step 4: Assemble the Technical Documentation Dossier

With the PMS and PMCF plans in place, assembling the technical documentation dossier is the next critical step in demonstrating compliance with regulatory requirements. The technical file must include extensive information regarding the safety and efficacy of the product. Below are the main components you must include:

• Device Description: Provide an exhaustive description of the drug-device combination product, detailing its intended use, working principles, and the specific characteristics that qualify it as a combination product.
• Risk Management: Include a risk management report that evaluates potential risks associated with the device and outlines risk control measures implemented to mitigate those risks. This should align with the ISO 14971 standard.
• PMS and PMCF Plans: Incorporate your finalized PMS and PMCF plans into the dossier, which will provide evidence of the company’s commitment to ongoing monitoring of product safety and effectiveness.
• Clinical Evaluation Report (CER): Prepare a comprehensive Clinical Evaluation Report that summarizes clinical data gathered during studies and through PMS/PMCF activities, demonstrating compliance with regulatory requirements detailed in Article 61 of the MDR.
• Lifecycle Management: Document strategies for product lifecycle management, highlighting monitoring and updates based on real-world data and clinical feedback.

The complete technical documentation dossier should not only meet regulatory compliance requirements but also serve as an effective communication tool for engaging with regulatory authorities, Notified Bodies, and stakeholders in discussions regarding your product.

Step 5: Submit the Dossier to Notified Bodies

After the technical documentation is compiled, the dossier is ready for submission to a Notified Body. The submission process is critical and involves a series of steps:

• Pre-Submission Consultation: Engage in a pre-submission consultation with the Notified Body if feasible. This can provide valuable insights and guidance before formally submitting your application.
• Documentation Review: Ensure all documents are thoroughly reviewed for completeness and alignment with EU MDR requirements. Attention to detail is paramount as any inconsistencies can lead to delays or rejections.
• Formal Submission: Submit your technical dossier along with the necessary fees to the chosen Notified Body. Ensure to keep track of submission receipts and correspondence.
• Follow-Up Communications: Maintain open lines of communication with the Notified Body post-submission. Be prepared for queries and provide additional information expeditiously as needed.
• Prepare for Audits: Understand that the Notified Body may conduct audits as part of the review process. Ensure that your internal processes are in line with regulatory standards, and documentation is readily available for review.

Approval from the Notified Body is crucial for the commercialization of your drug-device product in the EU. Maintain clear communication throughout the process to facilitate a smoother approval journey.

Step 6: Monitor Post-Market Performance and Compliance

Upon receiving approval and launching the drug-device combination product, continuous monitoring ensues. Ongoing PMS and PMCF activities are vital to ensure that your product remains compliant and safe for end-users. Here’s how to effectively monitor post-market performance:

• Data Collection and Identification of Signals: Utilize the methods established in your PMS plan to collect data continuously. Identify adverse events and any signals that warrant further investigation promptly.
• Update PMS and PMCF Plans: Regularly evaluate the effectiveness of your PMS and PMCF processes. Update these plans based on the latest data, ensuring they remain relevant to the evolving safety and performance landscape.
• Regulatory Reporting: Adhere to regulatory obligations to report adverse events or changes in risk profiles to the relevant authorities, including the EMA and Notified Bodies. The frequency and specifics of reporting will depend on the product classification and the nature of the reported events.
• Stakeholder Communication: Communicate findings from PMS and PMCF activities to stakeholders, including healthcare professionals, regulatory bodies, and patients. Effective communication will enhance trust and ensure that all parties remain informed about product performance.
• Collaborate with QA Teams: Work closely with Quality Assurance teams to ensure that all methodologies align with good manufacturing practices and required quality standards.

The post-market phase is a dynamic period, and companies must be proactive in addressing any regulatory or safety concerns promptly. Adapting to real-world data and feedback enhances product credibility and market relevance.

Step 7: Prepare for Renewals and Continuous Compliance

The regulatory landscape is ever-evolving, and it is essential to prepare for renewals and maintain continuous compliance. Understanding when and how to renew approvals is crucial. Here are the key considerations:

• Regulatory Renewal Timelines: Familiarize yourself with the renewal timelines established by the Notified Body. Ensure timely submissions to avoid gaps in compliance.
• Continuous Documentation Updates: Regularly update your technical documentation to reflect changes in your PMS and PMCF activities, as well as any amendments to the GSPR or other regulatory requirements.
• Engagement with Regulatory Authorities: Maintain an ongoing relationship with regulatory bodies. Engage in dialogues regarding regulatory changes and how they impact your product’s compliance and performance.
• Training and Education: Keep your team apprised of the latest regulatory changes and best practices. Continuous training and education are essential for adherence to evolving standards.

By anticipating the need for renewals and maintaining a culture of compliance within the organization, drug-device products can navigate the complexities of regulatory requirements while ensuring ongoing safety and efficacy for users.